Poly Medicure announced robust financial results for the second quarter and first half of FY27. Consolidated revenue grew by 30.8% year-on-year in Q2 FY27 to ₹580.5 crore. The company also achieved a consolidated operating EBITDA margin of 24.0%, within its guidance range. The results reflect strong performance across domestic and international markets, boosted by both organic growth and recent acquisitions.
Poly Medicure Delivers Strong Q2 and H1 FY27 Performance
Poly Medicure Limited has announced its financial results for the second quarter and first half of the financial year 2027, showcasing significant growth and operational strength. The company reported a consolidated revenue of ₹580.5 crore for Q2 FY27, marking a substantial 30.8% increase year-on-year. For the first half of FY27 (H1 FY27), consolidated revenue reached ₹1,105.9 crore, up 30.6% compared to the previous year.
Key Financial Highlights
The financial performance was characterized by strong top-line growth driven by both domestic and international segments. Domestic revenue grew by 22.0% in Q2 FY27 (19.3% in H1 FY27), while international revenue saw an impressive increase of 35.0% in Q2 FY27 (35.8% in H1 FY27). The company also highlighted organic revenue growth, with Q2 FY27 organic growth at 16.3% (H1 FY27 at 14.4%), demonstrating sustained underlying business momentum.
Profitability metrics remained solid, with consolidated operating EBITDA margin reported at 24.0% for Q2 FY27 and H1 FY27, falling within the guided range of 23-25%. Standalone operating EBITDA margin for Q2 FY27 stood at 27.4%, exceeding the guidance of 25-27%.
Strategic Updates and Product Development
The company provided updates on its key business initiatives, including the operationalization of its subsidiary Medyneo in Brazil, with the first shipment dispatched in October. Poly Medicure also established a direct UK presence to capitalize on opportunities under the India-UK FTA. Clinical deployment of DES units is showing month-on-month improvement, with approximately 18,000 units deployed as of October 2026. The PACIFIER DES clinical registry is progressing well, with over 1,150 patients enrolled.
In terms of product development, 12 new products have been launched to date in FY27, supported by an R&D team strength of over 90 professionals across India, Italy, and the Netherlands. The company also noted cumulative sales of approximately 1,250 dialysis machines and the addition of around 30 new customers across its key geographies.
Environmental, Social, and Governance (ESG) Initiatives
Poly Medicure continues its commitment to sustainability, with approximately 25.44% of its total energy consumption sourced from renewable energy. The company has achieved a significant 7.7x growth in solar power generation compared to the baseline Q2 FY25. Recently, the company was recognized with the “Excellence in Medical Technology” award by the Association of Healthcare Providers and “Service Provider of the Year – Medical Devices” by ET India.
Financial Performance Details
Standalone Financial Performance:
- Revenue from operations for Q2 FY27 was ₹488.3 crore, a 17.2% YoY increase.
- Gross Profit for Q2 FY27 stood at ₹336.3 crore, up 15.8% YoY, with a Gross Profit margin of 68.9%.
- Operating EBITDA for Q2 FY27 was ₹133.9 crore, a 20.3% increase YoY, with an EBITDA margin of 27.4%.
- For H1 FY27, standalone revenue was ₹919.4 crore (14.8% YoY growth), and Operating EBITDA was ₹254.8 crore (19.8% YoY growth) with a margin of 27.7%.
Consolidated Financial Performance:
- Consolidated Revenue for Q2 FY27 increased by 30.8% YoY to ₹580.5 crore.
- Consolidated Operating EBITDA for Q2 FY27 was ₹139.1 crore, a 20.1% increase YoY, with an EBITDA margin of 24.0%.
- For H1 FY27, consolidated revenue was ₹1,105.9 crore (30.6% YoY growth), and Operating EBITDA was ₹265.7 crore (19.2% YoY growth) with a margin of 24.0%.
The company maintains adequate liquidity, with ₹839.1 crore in cash and cash equivalents as of September 30, 2026.
Source: BSE
